CellaVision AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 07, 2024 at 01:20 am EST
Share
CellaVision AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 200.63 million compared to SEK 152.32 million a year ago. Net income was SEK 50.43 million compared to SEK 32.3 million a year ago. Basic earnings per share from continuing operations was SEK 2.11 compared to SEK 1.35 a year ago.
For the full year, sales was SEK 677.29 million compared to SEK 639.34 million a year ago. Net income was SEK 130.31 million compared to SEK 118.34 million a year ago. Basic earnings per share from continuing operations was SEK 5.46 compared to SEK 4.96 a year ago.
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision ABâs product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
CELLAVISION AB 
